Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jiangxi Rimag Group Co., Ltd. Class H ( (HK:2522) ) has issued an announcement.
Jiangxi Rimag Group Co., Ltd. has successfully completed the trading of its first batch of Annotation Data of CT Chest Lesions on the Beijing International Data Exchange. This milestone marks a significant step in promoting standardized integration and market-based trading of data elements, providing a new monetization model for the company’s core data assets and enhancing its market value in medical imaging data.
The most recent analyst rating on (HK:2522) stock is a Buy with a HK$52.39 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.
More about Jiangxi Rimag Group Co., Ltd. Class H
Jiangxi Rimag Group Co., Ltd. is a leading medical group in China specializing in medical imaging. It operates a medical imaging platform providing diversified imaging services and value across the medical imaging industry chain. The company offers imaging center services, imaging solution services, and Rimag Cloud services through its wholly-owned subsidiary, Beijing Rimag Information, which focuses on Rimag Cloud and data technology services.
Average Trading Volume: 20,883,389
Technical Sentiment Signal: Sell
For a thorough assessment of 2522 stock, go to TipRanks’ Stock Analysis page.